CD246 News

Latest News On CD246

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

6/1/2024 4:57 PM

Alectinib Approved for ALK-Positive Adjuvant NSCLC

4/22/2024 5:42 AM

Recommendations Guide Oral Immunotherapy for Food Allergies

4/16/2024 4:34 AM